Validation Data Gallery
|Positive WB detected in
|rat liver tissue, A549 cells, SGC-7901 cells
|Positive IP detected in
|mouse liver tissue
|Positive IHC detected in
|human liver tissue
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
|Positive IF detected in
|Western Blot (WB)
|WB : 1:500-1:2000
|IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate
|IHC : 1:20-1:200
|IF : 1:10-1:100
|It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
|Sample-dependent, check data in validation data gallery
The immunogen of 24766-1-AP is INSIG2 Fusion Protein expressed in E. coli.
|human, mouse, rat
|human, mouse, rat
|Host / Isotype
|Rabbit / IgG
|INSIG2 fusion protein Ag14072
|Calculated molecular weight
|225 aa, 25 kDa
|Observed molecular weight
|GenBank accession number
|Gene ID (NCBI)
|Antigen affinity purification
|PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
|Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA.
INSIG2 mediates feedback control of cholesterol synthesis by controlling SCAP and HMGCR. INSIG2 may bring HMGCR into ubiquitin-mediated proteasomal degradation. Insig2 protein are endoplasmic reticulum proteins that block the processing of sterol regulatory element binding proteins (SREBPs) by binding to SREBP cleavage-activating protein (SCAP), and thus prevent SCAP from escorting SREBPs to the Golgi. INSIG-2 may play an important role in therapy of hypercholesterolemia.
|Product Specific Protocols
|WB protocol for INSIG2 antibody 24766-1-AP
|IHC protocol for INSIG2 antibody 24766-1-AP
|IF protocol for INSIG2 antibody 24766-1-AP
|IP protocol for INSIG2 antibody 24766-1-AP
|Click here to view our Standard Protocols
The gluconeogenic enzyme PCK1 phosphorylates INSIG1/2 for lipogenesis.
CD36 promotes de novo lipogenesis in hepatocytes through INSIG2-dependent SREBP1 processing.
Int J Biol Sci
The GR-gp78 Pathway is involved in Hepatic Lipid Accumulation Induced by Overexpression of 11β-HSD1.
Am J Cancer Res
p38α/S1P/SREBP2 activation by the SAM-competitive EZH2 inhibitor GSK343 limits its anticancer activity but creates a druggable vulnerability in hepatocellular carcinoma.
A Multi-Level Systems Biology Analysis of Aldrin's Metabolic Effects on Prostate Cancer Cells
In vivo PAR-CLIP (viP-CLIP) of liver TIAL1 unveils targets regulating cholesterol synthesis and secretion